Close Menu

NEW YORK – Molecular diagnostic company Co-Diagnostics announced Thursday that it has entered into an agreement with institutional investors for a $4.2 million registered direct offering.

The offering is for the purchase of 470,000 shares of common stock at the purchase price of $9.00 per share, with the closing expected to occur on or before March 2, 2020.

The exclusive lead placement agent for the offering is HC Wainwright. Maxim Group is acting as co-placement agent.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.